OptimizeRx Q2 Earnings Call Highlights

The brief

OptimizeRx reported second-quarter fiscal 2026 revenue of $20.5 million, a 30% decrease from $29.2 million in the same period last year. The company's adjusted EBITDA for the quarter was $4.9 million. OptimizeRx reaffirmed its full-year revenue outlook of $95 million to $100 million. The company's financial performance is a key indicator of its progress in the healthcare technology sector. The earnings call highlights the company's financial position and future prospects.

Auto-summarised from the full article